Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection and Humoral Responses Against Different Variants of Concern in Domestic Pet Animals and Stray Cats from North-Eastern Spain.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Glucocorticoids' treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients.
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.